[{"orgOrder":0,"company":"Cerus Corporation","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Funding","leadProduct":"Pathogen Reduced Lyophilized Cryoprecipitate","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ U.S. Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Cerus Corporation \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Rusalatide Acetate","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Chrysalis BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chrysalis BioTherapeutics \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Chrysalis BioTherapeutics \/ BARDA"},{"orgOrder":0,"company":"Safi Biosolutions","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Safi Biosolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Safi Biosolutions \/ iBio","highestDevelopmentStatusID":"1","companyTruncated":"Safi Biosolutions \/ iBio"},{"orgOrder":0,"company":"MiMedx","sponsor":"U.S. Army Medical Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"Dehydrated Human Amnion Chorion Membrane","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiMedx \/ U.S. Army Medical Research and Development","highestDevelopmentStatusID":"1","companyTruncated":"MiMedx \/ U.S. Army Medical Research and Development"},{"orgOrder":0,"company":"Exalys Therapeutics","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"EP4 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Exalys Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exalys Therapeutics \/ Catalys Pacific","highestDevelopmentStatusID":"1","companyTruncated":"Exalys Therapeutics \/ Catalys Pacific"},{"orgOrder":0,"company":"University of Virginia School of Medicine","sponsor":"Adial Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"University of Virginia School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Virginia School of Medicine \/ Adial Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Virginia School of Medicine \/ Adial Pharmaceuticals"},{"orgOrder":0,"company":"NorthShore University HealthSystem","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"NorthShore University HealthSystem","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"NorthShore University HealthSystem \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"NorthShore University HealthSystem \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Entolimod","moa":"TLR5","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Statera Biopharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Statera Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Regenerative Epidermal Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Avita Medical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Avita Medical \/ Inapplicable"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Regenerative Epidermal Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avita Medical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Avita Medical \/ Inapplicable"}]

Find Novel Drugs for Trauma (Emergency, Injury, Surgery) under Development

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The RECELL® System technology platform, approved by the FDA for the treatment of acute thermal burns in both adults and children, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells.

                          Product Name : RECELL

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          September 11, 2022

                          Lead Product(s) : Regenerative Epidermal Cell

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Lead Product(s) : Dehydrated Human Amnion Chorion Membrane

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Study Phase : Undisclosed

                          Sponsor : U.S. Army Medical Research and Development

                          Deal Size : $4.6 million

                          Deal Type : Funding

                          Details : The award will be used to advance the clinical understanding of PURION® processed Dehydrated Human Amnion Chorion Membrane, specifically in treating acute injuries and preventing initially partial-thickness burns from deteriorating to full-thickness bur...

                          Product Name : DHACM

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 31, 2022

                          Lead Product(s) : Dehydrated Human Amnion Chorion Membrane

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : U.S. Army Medical Research and Development

                          Deal Size : $4.6 million

                          Deal Type : Funding

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Cerus’ LyoCryo, a pathogen reduced, lyophilized cryoprecipitate, is being designed for shelf stability, rapid availability, and portability, enabling administration to patients in remote environments with the aim of increasing survival from traumatic i...

                          Product Name : LyoCryo

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          February 11, 2022

                          Lead Product(s) : Pathogen Reduced Lyophilized Cryoprecipitate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : U.S. Department of Defense

                          Deal Size : $9.1 million

                          Deal Type : Funding

                          blank

                          04

                          University of Virginia School of Medicine

                          Country arrow
                          Peptide Therapy Summit
                          Not Confirmed

                          University of Virginia School of Medicine

                          Country arrow
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Under the Agreement, Purnovate will supply lead adenosine compounds and research team will be responsible for evaluating these compounds for efficacy and determination of the ideal formulations for maximum absorption with the goal of initiating future cl...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 28, 2021

                          Lead Product(s) : Adenosine Analog

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : Adial Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Statera is establishing a development program in Oncology and Hematology based on the potential that toll-like receptor 5 agonists, such as Entolimod, have shown in the treatment of neutropenia and anemia in cancer patients.

                          Product Name : CBLB502

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          January 12, 2021

                          Lead Product(s) : Entolimod

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The new company is focused on the development of first-in-class therapies for the treatment of inflammatory disorders with an initial target indication of the prevention of postoperative delirium.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 16, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : Catalys Pacific

                          Deal Size : $15.0 million

                          Deal Type : Series A Financing

                          blank

                          07

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The partners will develop a short-term treatment which includes intranasal delivery of low doses of N-acetylcysteine for mild Traumatic Brain Injury (mTBI) or concussion.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 01, 2020

                          Lead Product(s) : Acetylcysteine

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : ATAI Life Sciences

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          08

                          NorthShore University HealthSystem

                          Country arrow
                          Peptide Therapy Summit
                          Not Confirmed

                          NorthShore University HealthSystem

                          Country arrow
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Under the terms of the agreement, NorthShore University HealthSystem will study Eagle’s RYANODEX® (dantrolene sodium) for traumatic brain injury (TBI) in animal models.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 01, 2020

                          Lead Product(s) : Dantrolene

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : Eagle Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Annovis Bio filed a patent application with the USPTO concerning a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via by ANVS401 or related ...

                          Product Name : ANVS401

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 27, 2020

                          Lead Product(s) : Buntanetap

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : This study seeks to demonstrate that treatment with the RECELL System of partial-thickness burn injuries within 72-hours can safely increase the healing at day 10.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          April 03, 2020

                          Lead Product(s) : Autologous Regenerative Epidermal Cell

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank